Skoči na glavni sadržaj

Pregledni rad

Clinical Effects of Metoprolol Across the Cardiovascular Continuum.

Vjekoslav Tomulić ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska
David Gobić ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Milan Nikšić ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Tomislav Jakljević ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Zlatko Čubranić orcid id orcid.org/0000-0002-6989-5100 ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Luka Zaputović orcid id orcid.org/0000-0001-9415-9618 ; Klinički bolnički centar Rijeka, Rijeka, Hrvatska


Puni tekst: hrvatski pdf 103 Kb

str. 44-48

preuzimanja: 391

citiraj

Puni tekst: engleski pdf 103 Kb

str. 44-48

preuzimanja: 393

citiraj


Sažetak

Beta-adrenergetic receptor antagonists cause
positive effects across the whole cardiovascular continuum.
Compared to non-selective beta-blockers, cardioselective beta-1 blockers have an advantage in patients in whom we wish
to avoid beta-2 receptor blockade in the bronchi and peripheral blood vessels, in patients with bronchoobstructive and/or
peripheral arterial disease. A negative impact on blood glucose homeostasis and erectile function is to be avoided by selective application. Metoprolol has been internationally
known as widely applied and checked cardioselective betablocker for a long time. A series of clinical studies have clearly proved the therapeutic effect of metoprolol in the hypertension, acute and chronic types of coronary heart disease, postinfarction prophylaxis, heart arrhythmia and chronic heart failure syndrome. In all researches, metoprolol has showed good
tolerance and safety. If taking proper doses and managing patients properly, the side-effects are rare and reversible. Today,
metoprolol succinate is available in Croatia in the form with
sustained absorption and gradual plasma clearance with a
possibility of a one-day dosage which ensures stable concentration of the drug in the plasma and effects during a period of
24 hours. This is how a safer effect and better cooperation of
a patient required for the success of the treatment is achieved.

Ključne riječi

cardiovascular diseases; beta-blockers; metoprolol succinate

Hrčak ID:

71484

URI

https://hrcak.srce.hr/71484

Datum izdavanja:

30.3.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.656 *